Six- to seven-week-old male CB17 SCID mice (Janvier Labs, Le Genest-Saint-Isle, France) were injected subcutaneously with either 4 × 106 Panc-1 cells alone or Panc-1 together with PSCs at a 1 : 1 ratio. Each group consisted of five mice. Tumour growth was monitored two times per week. Tumour volumes (V) were calculated from the formula (V=length × height × width/2). The mice were killed under anaesthesia when V gained approximately 500 mm3. Tumours were collected and immediately snap frozen in liquid nitrogen. The xenograft experiments were performed in agreement with the local ethical committee (Utrecht University animal ethical board; ethical permit number is 2014.III.02.022).
Cb17 scid mice
Manufactured by Janvier Labs
Sourced in France
The CB17-SCID mice are an immunodeficient mouse model that lacks mature T and B cells. They are commonly used in biomedical research to study human diseases and test experimental therapies.
Automatically generated - may contain errors
Lab products found in correlation
5 protocols using cb17 scid mice
1
Xenograft Model for Pancreatic Cancer
2
Comparative Analysis of Tumor Models
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All animals used in the studies were handled with care, and experiments were done according to the guidelines from French legislation (Pten and N1ic models) or U.S. legislation (Hi-Myc model) and institutional policies. For the prostate cancer study, PB4-Cre (kindly provided by M. Chen), Ptenflox/+ (kindly provided by O. Lantz), Hi-Myc (Jackson laboratory), and Ezh2flox/+ (generously provided by A. Tarakhovsky) mice were used. For the breast cancer study, MMTV-Cre, Rosa-N1ic, and Ezh2flox/+ mice were used.
For xenografting experiments, 6-wk-old female CB17-SCID mice were purchased from Janvier Laboratories. MDA-MB-231 cells (1 × 106) were orthotopically injected into the mammary fat pads of 20 mice. Control cells (one of three alleles of EZH2 mutated) were grafted on the left side of each mouse, and EZH2− cells were grafted on the right side of each mouse. Mice were sacrificed 10 wk after injection, and the resulting tumors were measured and collected.
For xenografting experiments, 6-wk-old female CB17-SCID mice were purchased from Janvier Laboratories. MDA-MB-231 cells (1 × 106) were orthotopically injected into the mammary fat pads of 20 mice. Control cells (one of three alleles of EZH2 mutated) were grafted on the left side of each mouse, and EZH2− cells were grafted on the right side of each mouse. Mice were sacrificed 10 wk after injection, and the resulting tumors were measured and collected.
3
MINO MCL Xenograft Model and Drug Efficacy
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The MINO MCL xenograft model was generated by inoculating subcutaneously 6- to 7-week-old nude mice (Shanghai Ling Chang Experimental Animal Co., Ltd.) with 5 × 106 MINO cells. When tumor volume reached 100 to 200 mm3, animals were randomized into five groups of 8 to10 mice each, and were dosed orally with TG-1701 (25, 50, or 100 mg/kg, orally, twice a day), ibrutinib (100 mg/kg, orally, twice a day), or vehicle for 21 days. The tumor volume (V) was calculated as: V = 1/2 × a × b2, where a and b represent the length and width, respectively. In REC-1 and UPN-IbruR xenografts, CB17-SCID mice (Janvier labs) were inoculated subcutaneously with 107 REC-1GFP+Luc+ cells or UPN-IbruR cells and monitored for tumor growth, bioluminescence signal, and vital parameters as described previously (21 (link)), in compliance with the Animal Ethics Committee of the autonomous University of Barcelona (registry number 38/18). Tumor-bearing mice received either TG-1701 (25 mg/kg, every day) or ibrutinib (25 mg/kg, every day) for 17 days. Tumor samples were snap-frozen in OCT medium (Sakura Tissue Tek) or formalin-fixed and paraffin-embedded prior to immunohistochemical (IHC) staining with primary antibodies against Ikaros (Cell Signaling Technology) and CD20 (Beckman Coulter). Preparations were evaluated using an Olympus microscope and MicroManager software.
4
Diabetic Mouse Model Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Immunodeficient strain CB17/SCID mice (Janvier Labs, Le Genest-Saint-Isle, France) and db/db diabetic mouse strain (BKS.Cg-Dock7m+/+Leprdb J Genetically Engineered Inbred, The Jackson Laboratory) were kept in the animal house facility of the Institute for Neurosciences of Montpellier in ventilated and clear plastic boxes, subjected to standard light cycles (12 h to 90 lux light, 12 h dark). db/db mice are used to model phase 1 to 3 of diabetes type II and obesity. Mice homozygous for the diabetes spontaneous mutation (Leprdb) demonstrate morbid obesity, chronic hyperglycemia, pancreatic beta cell atrophy and hypoinsulinemic. The care, breeding and use of animals followed the animal welfare guidelines of the “Institut National de la Santé et de la Recherche Medicale” (INSERM), under the approval of the French “Ministère de l’Alimentation, de l’Agriculture et de la Pêche”, Approval Number CEEA-LR-11032).
5
Borrelia afzelii Infection in SCID Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Four-week-old female CB17scid mice from Janvier were subcutaneously infected with 105Borrelia afzelii BO23 strain in BSK medium. In parallel, a negative control group (n = 5) was injected with BSK medium. At 7 or 14 days post-inoculation mice (five mice per group at different times after infection) were sacrificed and the blood, heart, bladder, joints, skin at the inoculation site and ears were collected for DNA amplification and immunoassays. Two more mice were included in the study for plasma analysis at 14 days post-inoculation.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!